Skip to main content
Antimicrobial Agents and Chemotherapy logoLink to Antimicrobial Agents and Chemotherapy
. 2016 Apr 22;60(5):2807–2812. doi: 10.1128/AAC.02358-15

Compensatory Mutations of Rifampin Resistance Are Associated with Transmission of Multidrug-Resistant Mycobacterium tuberculosis Beijing Genotype Strains in China

Qin-jing Li a, Wei-wei Jiao a, Qing-qin Yin a, Fang Xu a, Jie-qiong Li a, Lin Sun a, Jing Xiao a, Ying-jia Li a, Igor Mokrousov c, Hai-rong Huang b,, A-dong Shen a,
PMCID: PMC4862491  PMID: 26902762

Abstract

Mycobacterium tuberculosis can acquire resistance to rifampin (RIF) through mutations in the rpoB gene. This is usually accompanied by a fitness cost, which, however, can be mitigated by secondary mutations in the rpoA or rpoC gene. This study aimed to identify rpoA and rpoC mutations in clinical M. tuberculosis isolates in northern China in order to clarify their role in the transmission of drug-resistant tuberculosis (TB). The study collection included 332 RIF-resistant and 178 RIF-susceptible isolates. The majority of isolates belonged to the Beijing genotype (95.3%, 486/510 isolates), and no mutation was found in rpoA or rpoC of the non-Beijing genotype strains. Among the Beijing genotype strains, 27.8% (89/320) of RIF-resistant isolates harbored nonsynonymous mutations in the rpoA (n = 6) or rpoC (n = 83) gene. The proportion of rpoC mutations was significantly higher in new cases (P = 0.023) and in strains with the rpoB S531L mutation (P < 0.001). In addition, multidrug-resistant (MDR) strains with rpoC mutations were significantly associated with 24-locus mycobacterial interspersed repetitive-unit–variable-number tandem-repeat clustering (P = 0.016). In summary, we believe that these findings indirectly suggest an epistatic interaction of particular mutations related to RIF resistance and strain fitness and, consequently, the role of such mutations in the spread of MDR M. tuberculosis strains.

INTRODUCTION

The worldwide emergence of drug-resistant tuberculosis (TB), especially multidrug-resistant (MDR) TB, is seriously threatening public health and poses a major threat to global TB control. China is one of the countries with a high burden of TB, accounting for about 20% of the global burden of MDR TB (1). According to a national survey of drug-resistant TB in China conducted in 2007 and 2008, 5.7% of patients with new cases of TB and 25.6% of patients with previously treated cases had MDR TB, presenting a serious challenge to TB control (2).

There are many factors contributing to the transmission of drug-resistant TB, including ineffective control programs, the presence of comorbidities, and numerous patient-related factors (36); however, the bacterial forces behind the spread of drug-resistant TB are not completely understood. Mathematical models predicted that the future of the drug-resistant TB epidemic would depend mostly on the fitness of drug-resistant Mycobacterium tuberculosis strains relative to that of drug-susceptible strains (7). Recent studies have shown that the drug-resistant strains can acquire one or more secondary mutations that will improve their fitness during evolution (8, 9).

Rifampin (RIF) is one of the important first-line anti-TB drugs and serves as a surrogate marker of MDR TB. RIF targets the β subunit of the RNA polymerase, encoded by the rpoB gene, and M. tuberculosis can acquire resistance to RIF through mutations in this gene, especially in the 81-bp RIF resistance-determining region (RRDR) (1012). Gagneux et al. (13) found that the acquisition of RIF resistance in laboratory-derived strains is usually accompanied by a fitness cost. However, in some clinical isolates harboring rpoB mutations, no fitness cost was found when the fitness of the isolates was compared with that of their parent wild-type isolates. Subsequent studies showed that some secondary mutations in the rpoA or rpoC gene can mitigate the initial fitness cost caused by an rpoB mutation (14, 15). In China, these putative compensatory mutations in rpoA and rpoC have not been studied yet, and it is unknown whether they contribute to the spread of drug-resistant TB in China.

In this study, we aimed to investigate the characteristics of the rpoA and rpoC mutations in clinical M. tuberculosis strains isolated in northern China and their role in the transmission of drug-resistant M. tuberculosis strains.

MATERIALS AND METHODS

Study population.

M. tuberculosis isolates were recovered from patients admitted to the Beijing Chest Hospital from January 2011 to December 2013. All strains isolated from patients living in Beijing and the adjacent provinces of Tianjin and Hebei found to be RIF resistant according to the initial drug susceptibility testing (DST) results were included in this study. RIF-susceptible strains were selected using a random-number table. This study was approved by the Health Research Ethics Committee of Beijing Chest Hospital, Capital Medical University.

DST.

The isolates were cultured on Lowenstein-Jensen medium for 4 weeks at 37°C. Testing for susceptibility to four first-line anti-TB drugs and four second-line drugs was performed by the absolute concentration method. The concentrations of the different drugs in the medium were as follows: isoniazid, 0.2 μg/ml; RIF, 50 μg/ml; streptomycin, 10 μg/ml; ethambutol, 5 μg/ml; ofloxacin, 2 μg/ml; levofloxacin, 2 μg/ml; amikacin, 30 μg/ml; and capreomycin, 40 μg/ml.

DNA extraction and sequencing.

DNA was extracted from mycobacterial cultures by the lysozyme, proteinase K, and cetyltrimethylammonium bromide procedure. Oligonucleotide primers were designed for PCR amplification and DNA sequencing using Primer software (v.3) (16) (Table 1). In this study, the entire rpoA gene (Rv3457c), the portion of the rpoC gene encoding the RpoA-RpoC interaction site (Rv0668; amino acids 351 to 760; previously shown to be prone to the acquisition of compensatory mutations [15]), and the core fragment of the rpoB gene (amino acids 395 to 598) were amplified and sequenced. The amplifications of rpoA and rpoC were performed using the following conditions: 5 min of denaturation at 95°C, followed by 35 amplification cycles (in which each cycle consisted of 94°C for 50 s, 64°C for rpoA2 and 67°C for rpoA1, rpoC1, and rpoC2 for 30 s, and 30 s of extension at 72°C) and an elongation step of 10 min at 72°C. The PCR conditions for rpoB were as follows: 3 min of denaturation at 95°C, followed by 35 amplification cycles (in which each cycle consisted of 94°C for 45 s, 62°C for 45 s, and 35 s of extension at 72°C) and an elongation step of 10 min at 72°C. DNA sequencing was carried out at the Tian Yi Hui Yuan Biotechnology Company (Beijing, China). Gene polymorphisms were identified by comparing the sequence of each isolate to the sequence of the corresponding gene of the H37Rv reference strain (GenBank accession no. NC_000962) using GeneDoc (v.3.2) software.

TABLE 1.

Primers used for DNA sequencing

Gene Positiona (bp) in reference to start position Orientation Oligonucleotide sequence (5′–3′) Tmb (°C)
rpoB RRDR 916 to 1572 Forward GGTCGCTATAAGGTCAACAAGAAG 59
Reverse GTACACGATCTCGTCGCTAACC 61
Complete rpoB
    rpoB1 −148 to 477 Forward TTGCGGCTCAGCGGTTTA 60
Reverse CGTGCCCTTCTCGGTCATC 61
    rpoB2 369 to 1027 Forward GCGGCTCCACTGTTCGTCA 63
Reverse GCAAGCGGACCAGAT 53
    rpoB3 1503 to 2114 Forward CCGTTCGGGTTCATCG 55
Reverse CCGTCGTCAGTACAGGGA 58
    rpoB4 2010 to 2666 Forward CGGTCCAACCACGGCACTT 63
Reverse TCACGCCCTTGTTGCC 63
    rpoB5 2592 to 3268 Forward GTGTATGTGGCTCAGAAACG 57
Reverse TGTCATCGGACTTGATGGTC 57
    rpoB6 3047 to 3534 (82 bp downstream) Forward GGTCACGGTTGGCTACA 59
Reverse CCGATGCGGAGTTCA 60
rpoA gene
    rpoA1 −30 to 595 (30 bp upstream) Forward TGGCGGACGTCGAAAGGAAGAA 66
Reverse TGGTCTCCACGTCCAGGATCAGC 67
    rpoA2 537 to 1068 (34 bp downstream) Forward TCCATCTACTCACCGGTGCTCAAA 63
Reverse CATAGCTGACGCTCCTGTCTGGAT 62
rpoC gene
    rpoC1 1030 to 1650 Forward ACCGCAGGGTGATCAACCGC 66
Reverse TTCGGCGCTCAAAGGCAGGT 66
    rpoC2 1589 to 2299 Forward GGCGTTCAATGCCGACTTCG 65
Reverse GGTTCAAAGCGCCACGCTGG 67
a

Position in reference to start position.

b

Tm, melting temperature.

Genotyping.

Members of the Beijing family of strains were identified by the RD105 multiplex PCR. The standard 24-locus variable-number tandem-repeat (VNTR) method (17) was used to genotype the M. tuberculosis isolates. Two or more isolates from different patients who shared the same 24-locus VNTR genotype patterns were considered clustered. Other isolates were classified as unique. We assumed that high-resolution 24-locus genotypic clustering represented the recent transmission of M. tuberculosis isolates.

Statistical analysis. The VNTR genotyping data were analyzed by use of the mycobacterial interspersed repetitive-unit (MIRU)–VNTR MIRU-VNTRplus web application (http://www.miru-vntrplus.org/MIRU/index.faces). Statistical analysis was performed with SPSS (v.16.0) software (SPSS Inc.). Univariate analysis of categorical variables was performed using chi-square and Fisher exact tests, as appropriate. Variables with a P value of less than 0.05 in the univariate analysis were further used in the multivariable logistic regression analysis.

RESULTS

Characteristics of study population and strains.

Among the total of 575 isolates selected, DST, genotyping, and DNA sequencing results were available for 510 isolates. The median age of the patients was 47 years (range, 8 to 90 years), and most patients (72.1%) were male. Of the 493 patients for whom data on treatment history were available, 260 (52.7%) had been previously treated. Among the 510 isolates, only 24 (4.7%) were non-Beijing family isolates, and none of the 12 non-Beijing family RIF-resistant strains harbored an rpoA or rpoC mutation. For this reason, the subsequent analysis was performed with 486 (95.3%) Beijing genotype isolates. According to the DST results, 320 Beijing family isolates were RIF resistant. Among these, 298 (93.1%) were MDR isolates, including 84 (26.3%) MDR sensu stricto, 138 (43.1%) pre-extensively drug-resistant (pre-XDR), and 76 (23.8%) XDR isolates.

Mutations in rpoA and rpoC.

All strains were analyzed for mutations in the rpoA gene and the RpoA-RpoC interaction site in the rpoC gene. Among 320 Beijing family strains, 27.8% (89/320 strains) harbored nonsynonymous mutations in the rpoA or rpoC gene (a single mutation per strain). A synonymous mutation in rpoC (D580D) was found in one isolate, and a synonymous mutation in rpoA (S30S) was found in two isolates. The mutations in rpoC occurred more frequently, accounting for 93.3% (83/89) of all the nonsynonymous mutations in rpoA and rpoC genes. A total of 31 different rpoC mutant variants were found, and 16 of these have not been described previously, to the best of our knowledge (Fig. 1). The most common mutated codons were rpoC codon 483 (33.7%, 28/83) and rpoC codon 491 (14.4%). Only six isolates (6.7%) showed nonsynonymous mutations in rpoA (in which four codons were concerned). In addition, 2 of 178 RIF-susceptible isolates harbored a nonsynonymous mutation in rpoC (T721C). Given that mutations in rpoA were extremely rare, only rpoC mutations were included in the further analysis.

FIG 1.

FIG 1

Nonsynonymous mutations identified in rpoA and rpoC of RIF-resistant isolates from China. The number of isolates is shown in parentheses.

The characteristics of RIF-resistant isolates with rpoC mutations.

Among the 83 RIF-resistant isolates with an rpoC mutation, 97.6% (81/83 isolates) were MDR isolates (including pre-XDR and XDR isolates) (Table 2). The proportion of pre-XDR and XDR isolates with an rpoC mutation was marginally higher than the proportion of MDR sensu stricto or RIF-monoresistant isolates with such a mutation (29.9% versus 20.2% and 9.1%, respectively; P = 0.066). Some characteristics of the patients infected with the strains with the rpoC mutation were further compared (Table 2). The isolates with an rpoC mutation were found more frequently in patients with newly diagnosed TB than in patients being retreated (37.2% versus 21.8%; P = 0.023).

TABLE 2.

Factors associated with nonsynonymous mutations in the rpoC gene in Beijing genotype isolatesa

Characteristic or variant No. (%) of isolates with:
OR (95% CI) P value for OR Adjusted OR (95% CI) P value for adjusted OR
rpoC mutation No rpoC mutation
Age (yr) 0.143
    ≥47 25 (18.5) 110 (81.5) 1 1
    25–47 38 (30.6) 86 (69.4) 1.94 (1.09–3.47) 0.023 1.23 (0.63–2.37)
    ≤25 18 (39.1) 28 (60.9) 2.83 (1.36–5.90) 0.005 2.33 (0.99–5.43)
    Unknown 2 13
Treatment history 0.023
    Retreatment 46 (21.8) 165 (78.2) 1 1
    New treatment 35 (37.2) 59 (62.8) 2.13 (1.25–3.62) 0.005 2.01 (1.10–3.65)
    Unknown 2 (12.5) 14 (87.5)
Resistance type 0.066
    RIF monoresistant 2 (9.1) 20 (90.9) 1 1
    MDR sensu stricto 17 (20.2) 67 (79.8) 2.54 (0.54–11.93) 0.225 1.21 (0.28–5.29)
    Pre-XDR and XDR 64 (29.9) 150 (70.1) 4.27 (0.97–18.79) 0.038 2.57 (0.65–10.21)
Mutation in rpoB <0.001
    Other mutations 7 (4.8) 138 (95.2) 1 1
    rpoB S531L 76 (43.4) 99 (56.6) 15.13 (6.69–34.23) <0.001 12.79 (5.54–29.56)
a

OR, odds ratio; CI, confidence interval.

Association between mutations in rpoC and the rpoB RRDR.

Sequencing of the rpoB gene (codons 395 to 598) from 320 RIF-resistant strains revealed that 308 (96.3%) isolates had at least one mutation in the RRDR, and these mainly involved codons 531 (61%), 526 (21.8%), and 516 (7.8%). The rpoB S531L mutation was the most common mutation (56.8%, 175/308 strains); in 12 strains, it was combined with another RRDR mutation. None of the 178 RIF-susceptible isolates harbored a mutation in the RRDR.

The rpoC mutations were significantly more often found to be associated with the rpoB S531L mutation than with the other rpoB mutations (43.4% versus 4.8%; P < 0.001; Table 2). A broad range of rpoC mutations was detected among isolates with the rpoB S531L mutation, in which a mutation in rpoC codon 483 was the most common (34.2%, 26/76). Among seven isolates with rpoC and other rpoB mutations, four harbored an rpoB mutation at codon 526, one harbored an rpoB mutation at codon 513, and one harbored an rpoB mutation at codon 533. In addition, one isolate with an rpoC W484G mutation did not show any mutation in the RRDR. The rest of the rpoB gene was then sequenced for this isolate, and the rpoB V146F mutation, which was previously reported to be associated with RIF resistance (18), was found.

rpoC mutations and transmission capacity of isolates.

Genetic clustering (by highly discriminatory VNTRs or IS6110-based restriction fragment polymorphism analysis [RFLP]) has been used extensively in molecular epidemiological studies as a measure of recent TB transmission. The underlying assumption was that TB patients infected with genotypically unique isolates represent cases of reactivation of latent infection, whereas patients with genetically clustered isolates are epidemiologically linked and represent chains of TB transmission.

In this study, three groups of isolates (RIF-monoresistant, MDR, and XDR isolates) did not differ with regard to clustering (Table 3). Since 97.5% of the isolates with rpoC mutations were MDR, further analysis focused on the MDR group. Out of 298 Beijing family MDR isolates, 114 were clustered isolates and 184 were orphans. Among the clustered isolates, 35.1% (40/114 isolates) harbored rpoC mutations. The most common mutations were in rpoC at codon 483 (35%, 14/40) and rpoC at codon 491 (22.5%, 9/40). Among the orphan isolates, 22.3% (41/184) harbored rpoC mutations, and those in rpoC at codon 483 were the most common (34.1%, 14/41). An rpoC mutation was found more frequently in clustered than nonclustered isolates (35.1% versus 22.3%; P = 0.016). We also detected rpoC mutations in 57.5% (23/40) of clustered isolates. The isolates in five and two of these clusters showed identical and different rpoC mutations, respectively. The other 16 clusters included isolates with and without rpoC mutations. Furthermore, the MDR isolates with both the rpoB S531L and rpoC mutations exhibited a higher clustering rate than those with the rpoB S531L mutation alone (49.3% versus 29.9%; P = 0.011).

TABLE 3.

Factors associated with transmissibility of Beijing genotype clinical isolates

Characteristic No. (%) of isolatesa
OR (95% CI)b P value
In the genotypic cluster Not in the genotypic cluster
Resistance type
    RIF monoresistant 9 (40.9) 13 (59.1) 1
    MDR 114 (38.3) 184 (61.7) 0.90 (0.37–2.16) 0.805
    XDR 31 (40.8) 45 (59.2) 0.99 (0.38–2.61) 0.992
Mutation type in MDR isolates
    No rpoC mutation 74 (34.1) 143 (65.9) 1
    rpoC mutation 40 (49.4) 41 (50.6) 1.89 (1.12–3.17) 0.016
    rpoB S531L mutation alone 26 (29.9) 61 (70.1) 1
    rpoB S531L and rpoC mutation 37 (49.3) 38 (50.7) 2.28 (1.19–4.35) 0.011
a

Defined by 24-locus MIRU-VNTR analysis.

b

OR, odds ratio; CI, confidence interval.

As noted above, two RIF-susceptible strains harbored the rpoC T721C mutation. Upon 24-locus VNTR typing, they were found to be orphans and were located in distant parts of the minimum-spanning tree (not shown).

DISCUSSION

Although M. tuberculosis strains of the Beijing family are, overall, widespread in China, they have always been overwhelmingly predominant in the northern part of the country (19, 20). The present study found no exception in this regard. The Beijing genotype was identified in 95.3% of the isolates in the collection studied, which led us to focus on a detailed comparative analysis of the Beijing family isolates. Recent studies suggested that many MDR TB cases result from patient-to-patient transmission rather than from the de novo acquisition of resistance during treatment (2, 21, 22). A population-based study in five provinces in China found that 43.7% of MDR isolates from individuals with clinical disease were in genetic clusters (3). This is similar to the findings of our study, where 38.3% of MDR strains and 40.8% of XDR strains were in clusters, indicating that circulating drug-resistant M. tuberculosis strains have the ability to efficiently spread in the population.

Whereas a causative role of rpoB mutations in RIF resistance in M. tuberculosis has been well-known for more than 20 years, the next valuable step in elucidating the genetic background of such isolates that are in circulation was made only relatively recently. Comas et al. (15) proposed that secondary mutations in the rpoA or rpoC gene could alleviate the fitness cost incurred by rpoB mutations, especially those in the RRDR. Subsequent studies found that mutations in the rpoA or rpoC gene were common in RIF-resistant clinical isolates from different countries, including South Africa, Russia, Ghana, Abkhazia/Georgia, Kazakhstan, and Uzbekistan, and about 90% of the mutations were located in the rpoC gene (4, 15, 23). In this study, mutations occurred more frequently in rpoC than rpoA (93.3%, 83/89 isolates). At the same time, the rpoC mutations showed a high level of diversity, but those in codons 483 and 491 were the most frequent (Fig. 1) which is concordant with the findings of the previous reports (4, 15, 23).

Inspired by the first publication of Comas et al. (15), this study did not analyze the entire rpoC gene but analyzed its most meaningful portion, which is the large portion involved in the RpoA-RpoC interaction. However, most recent research has described variations in rpoC beyond this core region (4, 24). In particular, in one geographically delimited setting in central Russia where TB was epidemic, 8% of isolates harbored such mutations in rpoC (4). The lack of analysis of the entire rpoC gene could be considered a limitation of our study. Accordingly, the prevalence rate of rpoC mutants in our setting could be somewhat underestimated, and an additional study is warranted in the future.

It is noteworthy that not all variations in the rpoA or rpoC gene represented the evolution of compensatory mutations. Instead, some single nucleotide polymorphisms in the rpoC gene were lineage-specific markers; e.g., rpoC A542A and rpoC G594E are markers of the Latin American Mediterranean (LAM) lineage and the Erdman strain (Haarlem lineage), respectively (15). With regard to the present study, two isolates with the rpoC T721C mutation were both RIF sensitive and genotypically distant (according to the 24-locus VNTR). Accordingly, this rpoC mutation is neither a lineage marker nor an RIF resistance marker and likely occurred independently in those two isolates; its function would best be assessed experimentally.

In this study, the RIF-resistant strains with rpoC mutations were prevalent in new cases, and the MDR strains with rpoC mutations were significantly associated with clustering. A similar study of 286 drug-resistant and 54 drug-susceptible M. tuberculosis isolates in the Western Cape Province of South Africa also found a higher prevalence of rpoC mutants among isolates clustered by IS6110-RFLP than nonclustered isolates (30.8% versus 9.4%) (23). de Vos et al. proposed that mutations in the rpoC gene (codons 245 to 560) contributed to the transmission of MDR TB (23), although they did not detail a putative mechanism for this contribution to transmission. Our results also demonstrate that there is some association between rpoC mutations and the spread of MDR strains, but the mechanism remains to be elucidated.

Here, the rpoC mutations were significantly associated with the rpoB S531L mutation, which is in accordance with the findings described in the previous publication (23) and is explained by the lower fitness cost of the rpoB S531L mutation (13). Mutations in rpoC can act by restoring structural interactions between the RNA polymerase β′, β, and α subunits (14). Furthermore, the rpoC mutants were more frequently found, albeit marginally, in pre-XDR and XDR groups of isolates than in MDR and RIF-monoresistant groups. These findings appear to support the hypothesis that epistatic interactions of different drug resistance and compensatory mutations are involved in the survival and evolution of drug-resistant M. tuberculosis (2527).

In conclusion, mutations occurred frequently in the rpoC genes of M. tuberculosis clinical strains isolated from the northern region of China and were seen more frequently in clustered than nonclustered isolates. We believe that the findings of this study indirectly suggest an epistatic interaction of particular mutations related to RIF resistance (i.e., rpoB versus rpoC) and strain fitness and, consequently, highlight the role of these mutations in the transmission of MDR M. tuberculosis.

ACKNOWLEDGMENTS

This work was supported by the National Natural Science Foundation of China (no. 81271889, no. 81541062) and the Open Project of the Beijing Key Laboratory of Capital Medical University (2014NYJH02).

REFERENCES

  • 1.World Health Organization. 2013. Global tuberculosis report 2013. Report WHO/HTM/MTB/2013.11. World Health Organization, Geneva, Switzerland. [Google Scholar]
  • 2.Zhao Y, Xu S, Wang L, Chin DP, Wang S, Jiang G, Xia H, Zhou Y, Li Q, Ou X, Pang Y, Song Y, Zhao B, Zhang H, He G, Guo J, Wang Y. 2012. National survey of drug-resistant tuberculosis in China. N Engl J Med 366:2161–2170. doi: 10.1056/NEJMoa1108789. [DOI] [PubMed] [Google Scholar]
  • 3.Yang C, Shen X, Peng Y, Lan R, Zhao Y, Long B, Luo T, Sun G, Li X, Qiao K, Gui X, Wu J, Xu J, Li F, Li D, Liu F, Shen M, Hong J, Mei J, DeRiemer K, Gao Q. 2015. Transmission of Mycobacterium tuberculosis in China: a population-based molecular epidemiologic study. Clin Infect Dis 61:219–227. doi: 10.1093/cid/civ255. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 4.Casali N, Nikolayevskyy V, Balabanova Y, Harris SR, Ignatyeva O, Kontsevaya I, Corander J, Bryant J, Parkhill J, Nejentsev S, Horstmann RD, Brown T, Drobniewski F. 2014. Evolution and transmission of drug-resistant tuberculosis in a Russian population. Nat Genet 46:279–286. doi: 10.1038/ng.2878. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 5.Wells CD, Cegielski JP, Nelson LJ, Laserson KF, Holtz TH, Finlay A, Castro KG, Weyer K. 2007. HIV infection and multidrug-resistant tuberculosis: the perfect storm. J Infect Dis 196(Suppl 1):S86–S107. doi: 10.1086/518665. [DOI] [PubMed] [Google Scholar]
  • 6.Gandhi NR, Nunn P, Dheda K, Schaaf HS, Zignol M, van Soolingen D, Jensen P, Bayona J. 2010. Multidrug-resistant and extensively drug-resistant tuberculosis: a threat to global control of tuberculosis. Lancet 375:1830–1843. doi: 10.1016/S0140-6736(10)60410-2. [DOI] [PubMed] [Google Scholar]
  • 7.Cohen T, Murray M. 2004. Modeling epidemics of multidrug-resistant M. tuberculosis of heterogeneous fitness. Nat Med 10:1117–1121. doi: 10.1038/nm1110. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 8.Müller B, Borrell S, Rose G, Gagneux S. 2013. The heterogeneous evolution of multidrug-resistant Mycobacterium tuberculosis. Trends Genet 29:160–169. doi: 10.1016/j.tig.2012.11.005. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 9.Maisnier-Patin S, Andersson DI. 2004. Adaptation to the deleterious effects of antimicrobial drug resistance mutations by compensatory evolution. Res Microbiol 155:360–369. doi: 10.1016/j.resmic.2004.01.019. [DOI] [PubMed] [Google Scholar]
  • 10.Zhao LL, Chen Y, Liu HC, Xia Q, Wu XC, Sun Q, Zhao XQ, Li GL, Liu ZG, Wan KL. 2014. Molecular characterization of multidrug-resistant Mycobacterium tuberculosis isolates from China. Antimicrob Agents Chemother 58:1997–2005. doi: 10.1128/AAC.01792-13. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 11.Yu XL, Wen ZL, Chen GZ, Li R, Ding BB, Yao YF, Li Y, Wu H, Guo XK, Wang HH, Zhang SL. 2014. Molecular characterization of multidrug-resistant Mycobacterium tuberculosis isolated from south-central in China. J Antibiot 67:291–297. doi: 10.1038/ja.2013.133. [DOI] [PubMed] [Google Scholar]
  • 12.Campbell PJ, Morlock GP, Sikes RD, Dalton TL, Metchock B, Starks AM, Hooks DP, Cowan LS, Plikaytis BB, Posey JE. 2011. Molecular detection of mutations associated with first- and second-line drug resistance compared with conventional drug susceptibility testing of Mycobacterium tuberculosis. Antimicrob Agents Chemother 55:2032–2041. doi: 10.1128/AAC.01550-10. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 13.Gagneux S, Long CD, Small PM, Van T, Schoolnik GK, Bohannan BJ. 2006. The competitive cost of antibiotic resistance in Mycobacterium tuberculosis. Science 312:1944–1946. doi: 10.1126/science.1124410. [DOI] [PubMed] [Google Scholar]
  • 14.Brandis G, Wrande M, Liljas L, Hughes D. 2012. Fitness-compensatory mutations in rifampicin-resistant RNA polymerase. Mol Microbiol 85:142–151. doi: 10.1111/j.1365-2958.2012.08099.x. [DOI] [PubMed] [Google Scholar]
  • 15.Comas I, Borrell S, Roetzer A, Rose G, Malla B, Kato-Maeda M, Galagan J, Niemann S, Gagneux S. 2011. Whole-genome sequencing of rifampicin-resistant Mycobacterium tuberculosis strains identifies compensatory mutations in RNA polymerase genes. Nat Genet 44:106–110. doi: 10.1038/ng.1038. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 16.Untergasser A, Cutcutache I, Koressaar T, Ye J, Faircloth BC, Remm M, Rozen SG. 2012. Primer3—new capabilities and interfaces. Nucleic Acids Res 40:e115. doi: 10.1093/nar/gks596. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 17.Supply P, Allix C, Lesjean S, Cardoso-Oelemann M, Rusch-Gerdes S, Willery E, Savine E, de Haas P, van Deutekom H, Roring S, Bifani P, Kurepina N, Kreiswirth B, Sola C, Rastogi N, Vatin V, Gutierrez MC, Fauville M, Niemann S, Skuce R, Kremer K, Locht C, van Soolingen D. 2006. Proposal for standardization of optimized mycobacterial interspersed repetitive unit-variable-number tandem repeat typing of Mycobacterium tuberculosis. J Clin Microbiol 44:4498–4510. doi: 10.1128/JCM.01392-06. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 18.Siu GK, Zhang Y, Lau TC, Lau RW, Ho PL, Yew WW, Tsui SK, Cheng VC, Yuen KY, Yam WC. 2011. Mutations outside the rifampicin resistance-determining region associated with rifampicin resistance in Mycobacterium tuberculosis. J Antimicrob Chemother 66:730–733. doi: 10.1093/jac/dkq519. [DOI] [PubMed] [Google Scholar]
  • 19.van Soolingen D, Qian L, de Haas PE, Douglas JT, Traore H, Portaels F, Qing HZ, Enkhsaikan D, Nymadawa P, van Embden JD. 1995. Predominance of a single genotype of Mycobacterium tuberculosis in countries of East Asia. J Clin Microbiol 33:3234–3238. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 20.Mokrousov I, Jiao WW, Sun GZ, Liu JW, Valcheva V, Li M, Narvskaya O, Shen AD. 2006. Evolution of drug resistance in different sublineages of Mycobacterium tuberculosis Beijing genotype. Antimicrob Agents Chemother 50:2820–2823. doi: 10.1128/AAC.00324-06. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 21.Seddon JA, Warren RM, Enarson DA, Beyers N, Schaaf HS. 2012. Drug-resistant tuberculosis transmission and resistance amplification within families. Emerg Infect Dis 18:1342–1345. doi: 10.3201/eid1808.111650. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 22.Zhao M, Li X, Xu P, Shen X, Gui X, Wang LL, Kathryn D, Mei J, Gao Q. 2009. Transmission of MDR and XDR tuberculosis in Shanghai, China. PLoS One 4:e4370. doi: 10.1371/journal.pone.0004370. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 23.de Vos M, Müller B, Borrell S, Black PA, van Helden PD, Warren RM, Gagneux S, Victor TC. 2013. Putative compensatory mutations in the rpoC gene of rifampin-resistant Mycobacterium tuberculosis are associated with ongoing transmission. Antimicrob Agents Chemother 57:827–832. doi: 10.1128/AAC.01541-12. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 24.Brandis G, Pietsch F, Alemayehu R, Hughes D. 2015. Comprehensive phenotypic characterization of rifampicin resistance mutations in Salmonella provides insight into the evolution of resistance in Mycobacterium tuberculosis. J Antimicrob Chemother 70:680–685. doi: 10.1093/jac/dku434. [DOI] [PubMed] [Google Scholar]
  • 25.Breen MS, Kemena C, Vlasov PK, Notredame C, Kondrashov FA. 2012. Epistasis as the primary factor in molecular evolution. Nature 490:535–538. doi: 10.1038/nature11510. [DOI] [PubMed] [Google Scholar]
  • 26.Borrell S, Gagneux S. 2011. Strain diversity, epistasis and the evolution of drug resistance in Mycobacterium tuberculosis. Clin Microbiol Infect 17:815–820. doi: 10.1111/j.1469-0691.2011.03556.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 27.Phillips PC. 2008. Epistasis—the essential role of gene interactions in the structure and evolution of genetic systems. Nat Rev Genet 9:855–867. doi: 10.1038/nrg2452. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from Antimicrobial Agents and Chemotherapy are provided here courtesy of American Society for Microbiology (ASM)

RESOURCES